Neuronetics Q3 2026 net loss narrows 83% to $1.56 million
STIM•Neuronetics’ third-quarter 2026 net loss narrowed 83% year over year to $1.56 million, while revenue rose 13% to $41.96 million. The company maintained FY26 revenue guidance at $160 million–$164 million and lowered operating expense guidance to $92.5 million–$95.5 million.
1. Quarterly results and guidance
Neuronetics’ third-quarter 2026 net loss narrowed 83% year over year to $1.56 million. Revenue rose 13% to $41.96 million, including a 20% increase in Greenbrook revenue to $26.19 million, while operating expenses fell 13% to $21.35 million, primarily due to lower sales and marketing expenses. FY26 revenue guidance remained $160 million–$164 million, and operating expense guidance fell to $92.5 million–$95.5 million.
2. Product and treatment updates
An accelerated TMS application remains under FDA review. A Wave Neuro agreement targets PTSD treatment, pending FDA clearance.
